微创机器人 20260304 摘要 微创机器人收入进入爆发期，2021-2025 年实现从零到 5.6 亿元增长， 预计 2026 年维持高增，2027 年有望实现盈亏平衡。 研发费用自 2022 年达峰后进入下行通道，产品矩阵趋于完整，核心驱 动力转向商业化落地与全球化扩张。 海外市场成为核心增量，2025 年出口增速超国内，预计 2026 年海外 订单达 120-200 台，5 年复合增速预期 25%-30%。 国产替代加速，达芬奇中国份额从 67%降至 40%+；公司图迈系列通 过"多孔+单孔+5G 远程"组合拳，技术追赶时滞缩短至 5 年。 政策端积极，2025 年注册证发放提速，北京、上海医保覆盖率达 60%- 80%，未来手术价格降至 2-3 万元将推动更多术式入保。 依托微创集团覆盖全球 2 万家医院的渠道优势，公司已在欧洲、东南亚 等区域放量，5G 远程手术量超 700 例领先全球。 Q&A 微创机器人自孵化以来的产品布局、核心产品进展及近 5 年收入与研发投入节 奏如何？ 公司在微创集团体系内孵化较早，通过产学研合作与高校协同，从早期样机逐 步推进到注册证获取，腔镜手术机器人在 2021 年 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海微创医疗机器人（集团）股份有限公司 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 6,599,543 | RMB | | 1 | RMB | | 6,599,543 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 6,599,543 | RMB | | 1 | RMB | | 6,599,543 | | 2. 股份分 ...

Group 1 - The core viewpoint of the article highlights a significant decline in the Hong Kong stock market, particularly among robotics concept stocks, with several companies experiencing notable drops in their share prices [1] - The article mentions that after the performance of Yushu Technology's robot last year, four more robotics companies showcased their products on CCTV this year, which has reignited interest in humanoid robots [1] - Despite the renewed interest in robotics, the rental prices for robots are reportedly falling sharply, with daily rental fees dropping below 100 yuan [1] Group 2 - Specific companies that experienced declines include: - Woan Robotics down 10.20% with a market cap of 32.744 billion yuan - Cheng5 Ray down 9.96% with a market cap of 18.619 billion yuan - Shou Cheng Holdings down 8.94% with a market cap of 17.707 billion yuan - Fan Shi Intelligent down 9.42% with a market cap of 21.172 billion yuan - Sanhua Intelligent Control down 6.68% with a market cap of 150.563 billion yuan - Other notable declines include UBTECH, SenseTime-W, and others [2]

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

Core Viewpoint - The Hong Kong stock market has seen a significant surge in AI application stocks, with notable increases in share prices and market capitalizations for several companies [1]. Group 1: Company Performance - Zhizhu (智谱) experienced a remarkable increase of 42.72%, reaching a peak price of 725 HKD, with a total market capitalization surpassing 320 billion HKD [2]. - MINIMAX-WP saw a rise of 14.52%, with its market value also exceeding 300 billion HKD [2]. - Haizhi Technology Group (海致科技集团) surged over 28%, achieving a new high since its listing [1]. Group 2: Year-to-Date Performance - Zhizhu's year-to-date increase stands at 523.92% [2]. - Haizhi Technology Group has recorded a year-to-date rise of 469.48% [2]. - MINIMAX-WP's year-to-date performance shows an increase of 487.88% [2].

Core Viewpoint - The Hong Kong stock market saw a significant rise in robotics concept stocks, driven by the showcase of humanoid robots during the Spring Festival Gala, leading to increased consumer interest and sales in related products [1][2]. Group 1: Market Performance - Robotics stocks such as Yujian surged over 18%, Suton Jichuang increased by over 11%, and Shoucheng Holdings rose by 9% [1]. - Other notable gains included Youbixuan with nearly 9%, Yunjie, Sanhua Intelligent Control, and Jizhi Jia-W each rising over 6%, while MicroPort Scientific and Lijin Technology increased by over 5% [1]. - The total market capitalization for these companies varied, with Youbixuan at 757.12 billion, and Shoucheng Holdings at 189.48 billion [2]. Group 2: Sales Growth - During the Spring Festival period from February 16 to 18, Douyin e-commerce reported a 1680% year-on-year increase in GMV for robot products, with order volume rising by 655% [1]. - The "Spring Festival Gala" effect contributed to the popularity of related products, as several emerging humanoid robot startups showcased their innovations during the event [1].

微创机器人主要提供用于微创手术的手术机器人，其中"图迈"及"鸿鹄"分别为其在腹腔镜及骨科领域的 核心产品。"图迈"是首款经临床验证疗效不逊于达文西手术系统的中国国产腹腔镜手术机器人，而达文 西手术系统乃直觉外科公司(Intuitive Surgical)目前在中国及全球的领先产品。该行相信此项成就确立了 微创机器人作为中国本土龙头企业的地位，使其能够受惠于进口替代趋势。 摩根大通发布研报称，予微创机器人-B(02252)"增持"评级，目标价为41港元。微创机器人核心产品"图 迈"累计订单已突破200台，意味自2026年1月下旬以来新增约20台订单，延续2025年10月至2026年1月的 强劲势头，持续缓解市场对其可持续性的部分担忧。覆盖范围已扩展至逾50个国家及地区(2025年12月 底为40多个)，其中12个市场订购超过五台，主要由新兴市场如印度及巴西领军，而西班牙、澳洲等发 达市场亦取得加速突破。 ...

微创机器人主要提供用于微创手术的手术机器人，其中"图迈"及"鸿鹄"分别为其在腹腔镜及骨科领域的 核心产品。"图迈"是首款经临床验证疗效不逊于达文西手术系统的中国国产腹腔镜手术机器人，而达文 西手术系统乃直觉外科公司(Intuitive Surgical)目前在中国及全球的领先产品。该行相信此项成就确立了 微创机器人作为中国本土龙头企业的地位，使其能够受惠于进口替代趋势。 智通财经APP获悉，摩根大通发布研报称，予微创机器人-Ｂ(02252)"增持"评级，目标价为41港元。微 创机器人核心产品"图迈"累计订单已突破200台，意味自2026年1月下旬以来新增约20台订单，延续2025 年10月至2026年1月的强劲势头，持续缓解市场对其可持续性的部分担忧。覆盖范围已扩展至逾50个国 家及地区(2025年12月底为40多个)，其中12个市场订购超过五台，主要由新兴市场如印度及巴西领军， 而西班牙、澳洲等发达市场亦取得加速突破。 ...

格隆汇2月13日丨微创机器人-B(02252.HK)宣布，公司已收到联交所授出日期为2026年2月13日就 5,989,798股H股(「转换H股」)(即将予转换及上市的非上市股份的总数)上市及买卖的批准。 ...

Group 1 - The company MicroPort Scientific Corporation (02252) has received approval from the Hong Kong Stock Exchange for the listing and trading of 5.9898 million H shares, which are to be converted and listed [1] - The conversion and listing will involve a total of 5.9898 million non-listed shares held by two shareholders, representing approximately 0.5808% of the total issued shares of the company as of the announcement date [1]